Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non–small-cell Lung Cancer

Takahisa Kawamura, Hirotsugu Kenmotsu, Shota Omori, Kazuhisa Nakashima, Kazushige Wakuda, Akira Ono, Tateaki Naito, Haruyasu Murakami, Katsuhiro Omae, Keita Mori, Yusuke Tanigawara, Takashi Nakajima, Yasuhisa Ohde, Masahiro Endo, Toshiaki Takahashi

Research output: Contribution to journalArticlepeer-review

23 Citations (Scopus)

Abstract

A higher T790M detection rate is desirable for introducing third-generation epidermal growth factor receptor-tyrosine kinase inhibitor treatment. This study evaluated the clinical factors influencing the incidence of T790M. Postsurgery recurrence and longer total duration of epidermal growth factor receptor-tyrosine kinase inhibitor treatment before rebiopsy correlated with high incidence of T790M mutation. Therefore, rebiopsy after disease progression is aggressively encouraged in patients with these factors. Background: T790M, a secondary epidermal growth factor receptor (EGFR) mutation, accounts for approximately 50% of acquired resistance to EGFR-tyrosine kinase inhibitors (TKIs). To facilitate the use of third-generation EGFR-TKIs to potentially overcome T790M-mediated resistance, we evaluated the clinical factors influencing the incidence of T790M mutation. Patients and Methods: We retrospectively screened patients with non–small-cell lung cancer harboring EGFR mutations with progressive disease who were rebiopsied between January 2013 and December 2016. Factors influencing T790M status were evaluated by univariate and multivariate analysis. Results: Among 131 rebiopsied patients for whom EGFR mutation status was available, 58 (44%) had T790M mutations. Patient characteristics at rebiopsy were not significantly different between T790M-positive and -negative groups, except for surgical history (postsurgery recurrence). Total duration of EGFR-TKI treatment before rebiopsy, TKI-free interval, EGFR-TKI treatment history immediately before rebiopsy, continuation of initial EGFR-TKI beyond progressive disease, progression-free survival after initial TKI treatment, and rebiopsy site (other than fluid samples) significantly influenced T790M status. The incidence of T790M mutation was shown by multivariate analysis to be significantly higher in patients with postsurgery recurrence and total duration of EGFR-TKI treatment ≥ 1 year before rebiopsy (odds ratio, 4.2; 95% confidence interval, 1.3-15.7 and odds ratio, 4.4; 95% confidence interval, 1.1-19.8, respectively). Conclusion: Postsurgery recurrence and longer total duration of EGFR-TKI treatment before rebiopsy may represent useful predictive markers for T790M detection. In patients with these clinical factors, rebiopsies are more recommended to detect T790M mutation.

Original languageEnglish
Pages (from-to)e247-e252
JournalClinical Lung Cancer
Volume19
Issue number2
DOIs
Publication statusPublished - 2018 Mar

Keywords

  • Acquired resistance
  • Disease progression
  • EGFR-TKI
  • Epidermal growth factor receptor
  • Predictive marker

ASJC Scopus subject areas

  • Oncology
  • Pulmonary and Respiratory Medicine
  • Cancer Research

Fingerprint Dive into the research topics of 'Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non–small-cell Lung Cancer'. Together they form a unique fingerprint.

Cite this